Inventor · disambiguated record
Brandon Wustman
Also filed as: WUSTMAN BRANDON · WUSTMAN BRANDON A · WUSTMAN BRANDON ALAN
23 granted patents·30 pending applications·383 citations·filing 2006–2024
96Inventor score
Files withRECODE THERAPEUTICS INC22AMICUS THERAPEUTICS INC17TRANSCRIPTX INC6WUSTMAN BRANDON3AMICUS THERAPEUTICS2
Top patents by PatentIndex Score
53 records- 0198USRE48608EMethod to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS INC·Filed 2018·Granted Jun 29, 2021·36 cites·44 claims
- 0298US10813921B2Method to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS INC·Filed 2018·Granted Oct 27, 2020·39 cites·18 claims
- 0398US9545397B2Method to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS INC·Filed 2015·Granted Jan 17, 2017·50 cites·1 claims
- 0497US9056101B2Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperonesLOCKHART DAVID J·Filed 2008·Granted Jun 16, 2015·67 cites·7 claims
- 0596US8592362B2Method to predict response to pharmacological chaperone treatment of diseasesBENJAMIN ELFRIDA·Filed 2010·Granted Nov 26, 2013·112 cites·4 claims
- 0694US11786610B2Treatment of primary ciliary dyskinesia with synthetic messenger RNATRANSCRIPTX INC·Filed 2022·Granted Oct 17, 2023·4 cites·20 claims
- 0794US11510997B2Treatment of primary ciliary dyskinesia with synthetic messenger RNATRANSCRIPTX INC·Filed 2022·Granted Nov 29, 2022·5 cites·26 claims
- 0894US9095584B2Method to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS·Filed 2013·Granted Aug 4, 2015·52 cites·10 claims
- 0990US12121610B2Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2023·Granted Oct 22, 2024·3 cites·32 claims
- 1090US11642421B2Treatment of primary ciliary dyskinesia with synthetic messenger RNATRANSCRIPTX INC·Filed 2020·Granted May 9, 2023·2 cites·65 claims
- 1189US12133923B2Lipid nanoparticle compositions and uses thereofRECODE THERAPEUTICS INC·Filed 2024·Granted Nov 5, 2024·2 cites·25 claims
- 1288US12337068B2Lipid nanoparticle compositions and uses thereofRECODE THERAPEUTICS INC·Filed 2024·Granted Jun 24, 2025·1 cites·28 claims
- 1386US7829579B2Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidaseAMICUS THERAPEUTICS INC·Filed 2007·Granted Nov 9, 2010·6 cites·14 claims
- 1482US2024374513A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1582US2024374514A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1682US2024390271A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1782US2024374512A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1882US2024390272A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1982US2024374511A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2081US2024285798A1Treatment of primary ciliary dyskinesia with synthetic messenger rnaTRANSCRIPTX INC·Filed 2023·Application pending·0 cites
- 2180US12257318B2Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Granted Mar 25, 2025·0 cites·30 claims
- 2279US2025276091A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2379US2023338411A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2479US2024299310A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2579US2024277850A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2679US2024261432A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2776US10064851B2Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidaseAMICUS THERAPEUTICS INC·Filed 2016·Granted Sep 4, 2018·1 cites·13 claims
- 2876US7964617B2Methods for treating parkinsons disease and parkinsonismAMICUS THERAPEUTICS INC·Filed 2006·Granted Jun 21, 2011·1 cites·6 claims
- 2976US2025082621A9Method To Predict Response To Pharmacological Chaperone Treatment Of DiseasesAMICUS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3075US2024207178A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3172US2024398983A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3271US9675627B2Dosing regimens for treating and/or preventing cerebral amyloidosesAMICUS THERAPEUTICS INC·Filed 2015·Granted Jun 13, 2017·1 cites·16 claims
- 3370US2019117796A1Treatment of primary ciliary dyskinesia with synthetic messenger rnaTRANSCRIPTX INC·Filed 2018·Application pending·0 cites
- 3470US2019111074A1Treatment of primary ciliary dyskinesia with synthetic messenger rnaTRANSCRIPTX INC·Filed 2018·Application pending·0 cites
- 3568US2025019409A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3667US9119845B2Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidaseWUSTMAN BRANDON ALAN·Filed 2010·Granted Sep 1, 2015·1 cites·17 claims
- 3766US9597324B2Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymesAMICUS THERAPEUTICS INC·Filed 2014·Granted Mar 21, 2017·0 cites·10 claims
- 3865US9402837B2Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidaseAMICUS THERAPEUTICS INC·Filed 2014·Granted Aug 2, 2016·0 cites·13 claims
- 3959US2024216515A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4059US2017003301A1Method to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS·Filed 2016·Application pending·0 cites
- 4157US2017273996A1Dosing Regimens for Treating And/Or Preventing Cerebral AmyloidosesAMICUS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4257US2018133206A1Treatment of CNS Disorders Associated with Mutations in Genes Encoding Lysosomal EnzymesAMICUS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4357US2024197641A1Compositions and methods for targeted systemic delivery to cellsRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4456US2011152319A1Method to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS INC·Filed 2010·Application pending·0 cites
- 4555US2025114477A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4653US8883813B2Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymesWUSTMAN BRANDON·Filed 2011·Granted Nov 11, 2014·0 cites·7 claims
- 4753US2024123087A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4852US2011136151A1Assays for diagnosing and evaluating treatment options for pompe diseaseAMICUS THERAPEUTICS INC·Filed 2009·Application pending·0 cites
- 4952US2011189710A1TREATMENT OF POMPE DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARkERSAMICUS THERAPEUTICS INC·Filed 2009·Application pending·0 cites
- 5049US9931353B2Method for treating cerebral amyloid angiopathy using pharmacological chaperones to increase the activity of gangliosidasesAMICUS THERAPEUTICS INC·Filed 2015·Granted Apr 3, 2018·0 cites·6 claims
Showing the top 50 of 53 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →